A phase II study of durvalumab re-treatment plus /- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ellis, Peter Michael
  • Taylor, Sara Kristina
  • Bradbury, Penelope Ann
  • Goffin, John
  • Juergens, Rosalyn A
  • Laurie, Scott A
  • Liu, Geoffrey
  • Spratlin, Jennifer L
  • Chau, Nicole Grace
  • Charpentier, Danielle
  • Coschi, Courtney
  • Sederias, Joana
  • Zhang, Siwei
  • Tu, Dongsheng
  • Seymour, Lesley
  • Gaudreau, Pierre-Olivier

publication date

  • June 1, 2023